OncoPep
OncoPep, Inc. was founded in 2010 to commercialize a novel approach to developing targeted immunotherapeutics against cancer. The company's proprietary core technology was developed in the laboratory of Dr. Kenneth Anderson, M.D., a world leader in cancer treatment, at the Dana Farber Cancer Institute. The technology, which OncoPep has exclusively licensed from Dana Farber, employs a unique combination of proprietary peptides to form a therapeutic cancer vaccine. Vaccines developed from this technology are designed to stimulate the patient’s immune system to attack his or her cancer through an optimized combination of disease-specific peptides and adjuvants (substances that stimulate the immune system).
Industries
Nr. of Employees
small (1-50)
OncoPep
North Andover, Massachusetts, United States, North America
Patents
Products
PVX-410
An investigational multi-peptide therapeutic cancer vaccine targeting tumor-associated antigens to stimulate cytotoxic T lymphocytes in patients with triple negative breast cancer and smoldering multiple myeloma.
MTAA-420
An investigational autologous multi-tumor antigen adoptive T cell therapy developed to target multiple antigens expressed on tumors, initially for multiple myeloma treatment.
PVX-024/PVX-510 (2nd Generation Vaccines)
Next-generation multi-peptide cancer vaccines designed to improve upon initial vaccine iterations and expand coverage to additional HLA subtypes such as HLA-A24.
PVX-410
An investigational multi-peptide therapeutic cancer vaccine targeting tumor-associated antigens to stimulate cytotoxic T lymphocytes in patients with triple negative breast cancer and smoldering multiple myeloma.
MTAA-420
An investigational autologous multi-tumor antigen adoptive T cell therapy developed to target multiple antigens expressed on tumors, initially for multiple myeloma treatment.
PVX-024/PVX-510 (2nd Generation Vaccines)
Next-generation multi-peptide cancer vaccines designed to improve upon initial vaccine iterations and expand coverage to additional HLA subtypes such as HLA-A24.